文献速递类风湿关节炎

类风湿关节炎累积患者报告疾病活动度监测可预测持续缓解、复发与治疗升级

Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-21

本研究纳入100例类风湿关节炎(RA)患者,每两周居家记录患者疾病活动度评分2(PDAS2),计算时间累积PDAS2(cPDAS2),评估其预测持续缓解/低疾病活动度(LDAS)、复发和治疗升级的能力。cPDAS2预测Boolean/SDAI缓解的敏感性为93%/84%;cPDAS2≥0.29预测复发(P=0.04,特异性79%,阴性预测值88%);cPDAS2≥4.33和/或ΔcPDAS2≥0.059预测治疗升级。居家PDAS2监测可行,cPDAS2有助于预测复发和治疗升级。

要点

  • 居家PDAS2完成率92%,中位每15天记录7.5次,随访16周。
  • cPDAS2≥0.29预测复发,特异性79%,阴性预测值88%。
  • cPDAS2≥4.33且ΔcPDAS2≥0.059预测治疗升级,特异性88%,阴性预测值89%。

核心结论

  • 居家PDAS2监测可行,cPDAS2有助于预测RA患者复发和治疗升级。

研究设计与样本

  • 招募100例RA患者,在两次门诊之间每两周居家记录PDAS2,医生根据门诊疾病活动度调整治疗且对居家PDAS2盲态。
  • cPDAS2由所有PDAS2评分的曲线下面积计算,并与两次门诊时的疾病活动度比较。

主要发现

  • 患者平均年龄59岁,平均RA病程14年,女性占90%,血清阳性71%,64%处于缓解/LDAS。
  • cPDAS2预测两次门诊时Boolean/SDAI缓解、DAS28、SDAI和CDAI缓解或LDAS的敏感性分别为93%、84%、73%和80%。
  • cPDAS2≥0.29预测复发(P=0.04),特异性79%,阴性预测值88%。
  • cPDAS2≥4.33且ΔcPDAS2≥0.059预测治疗升级(P=0.007),特异性88%,阴性预测值89%。
  • cPDAS2≥4.33或ΔcPDAS2≥0.059预测治疗升级(P=0.02),敏感性和阴性预测值均为100%。

关键数值与推荐

  • cPDAS2≥0.29为预测复发的最佳切点,特异性79%,阴性预测值88%。
  • cPDAS2≥4.33且ΔcPDAS2≥0.059为预测治疗升级的切点,特异性88%,阴性预测值89%。
  • cPDAS2≥4.33或ΔcPDAS2≥0.059预测治疗升级的敏感性和阴性预测值均为100%。

临床怎么用

  • RA患者可每两周居家记录PDAS2,累积cPDAS2可用于辅助预测复发风险和治疗升级需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patient-based Disease Activity Score 2 (PDAS2) had been developed for RA patients to self-assess and record disease activity in between clinic visits. This study explored the clinical utility of time-integrated cumulative PDAS2 (cPDAS2) on predicting sustained remission or low disease activity state (LDAS), flare and treatment escalation. METHODS: We recruited 100 patients to record PDAS2 at home fortnightly between two consecutive clinic visits. Rheumatologists adjusted treatment according to disease activity recorded during clinic consultation while blinded to home PDAS2 scores. cPDAS2 calculated from the area-under-curve of all PDAS2 scores were compared with disease activities at both visits. cPDAS2 and ΔcPDAS2 (change from PDAS2 at the first visit) were tested to determine their ability to predict ACR/EULAR remission, SDAI flare-up (from remission/LDAS to moderate/high disease activity) and treatment escalation. Optimal cut-points were determined by Receiver Operator Characteristic curve. RESULTS: Mean age of the patients was 59 years, mean RA duration 14 years, 90% were female, 71% seropositive and 64% in remission/LDAS. The home PDAS2 completion rate was 92%. PDAS2 scores were done 7.5 times every 15 days over a 16-week follow-up (all medians). The sensitivity of cPDAS2 in predicting Boolean/SDAI remission at two visits, DAS28, SDAI and CDAI remission or LDAS were 93%, 84%, 73% and 80% respectively. cPDAS2 ≥ 0.29 predicted flare (P = 0.04), with specificity 79% and negative predicting value (NPV) 88%. Rheumatologists' decision to escalate treatment was predicted by (cPDAS2 ≥ 4.33 and ΔcPDAS2 ≥ 0.059) (P = 0.007) with specificity 88% and NPV 89%, and (cPDAS2 ≥ 4.33 or ΔcPDAS2 ≥ 0.059) (P = 0.02) with both sensitivity and NPV 100%. CONCLUSION: PDAS2 monitoring at home is feasible. cPDAS2 is useful to predict flare and treatment escalation.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Leung MH, Choy EHS, Lau CS, et al. Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation. Semin Arthritis Rheum. 2020. PMID: 32531504. doi:10.1016/j.semarthrit.2020.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。